TY - JOUR
T1 - Injectable nanomaterials for drug delivery
T2 - Carriers, targeting moieties, and therapeutics
AU - Webster, David M.
AU - Sundaram, Padma
AU - Byrne, Mark E.
N1 - Funding Information:
This research was supported by the US Department of Education (Grant #P200A60184 ); DMW was a US Department of Education GAANN Fellow. We also acknowledge the Alabama Commission on Higher Education ACHE-GRSP (Grant G00006238 , PS was an ACHE Graduate Research Scholar) for funding this project.
PY - 2013/5
Y1 - 2013/5
N2 - Therapeutics such as nucleic acids, proteins/peptides, vaccines, anti-cancer, and other drugs have disadvantages of low bio-availability, rapid clearance, and high toxicity. Thus, there is a significant need for the development of efficient delivery methods and carriers. Injectable nanocarriers have received much attention due to their vast range of structures and ability to contain multiple functional groups, both within the bulk material and on the surface of the particles. Nanocarriers may be tailored to control drug release and/or increase selective cell targeting, cellular uptake, drug solubility, and circulation time, all of which lead to a more efficacious delivery and action of therapeutics. The focus of this review is injectable, targeted nanoparticle drug delivery carriers highlighting the diversity of nanoparticle materials and structures as well as highlighting current therapeutics and targeting moieties. Structures and materials discussed include liposomes, polymersomes, dendrimers, cyclodextrin-containing polymers (CDPs), carbon nanotubes (CNTs), and gold nanoparticles. Additionally, current clinical trial information and details such as trial phase, treatment, active drug, carrier sponsor, and clinical trial identifier for different materials and structures are presented and discussed.
AB - Therapeutics such as nucleic acids, proteins/peptides, vaccines, anti-cancer, and other drugs have disadvantages of low bio-availability, rapid clearance, and high toxicity. Thus, there is a significant need for the development of efficient delivery methods and carriers. Injectable nanocarriers have received much attention due to their vast range of structures and ability to contain multiple functional groups, both within the bulk material and on the surface of the particles. Nanocarriers may be tailored to control drug release and/or increase selective cell targeting, cellular uptake, drug solubility, and circulation time, all of which lead to a more efficacious delivery and action of therapeutics. The focus of this review is injectable, targeted nanoparticle drug delivery carriers highlighting the diversity of nanoparticle materials and structures as well as highlighting current therapeutics and targeting moieties. Structures and materials discussed include liposomes, polymersomes, dendrimers, cyclodextrin-containing polymers (CDPs), carbon nanotubes (CNTs), and gold nanoparticles. Additionally, current clinical trial information and details such as trial phase, treatment, active drug, carrier sponsor, and clinical trial identifier for different materials and structures are presented and discussed.
UR - http://www.scopus.com/inward/record.url?scp=84876934723&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84876934723&partnerID=8YFLogxK
U2 - 10.1016/j.ejpb.2012.12.009
DO - 10.1016/j.ejpb.2012.12.009
M3 - Review article
C2 - 23313176
AN - SCOPUS:84876934723
SN - 0939-6411
VL - 84
SP - 1
EP - 20
JO - European Journal of Pharmaceutics and Biopharmaceutics
JF - European Journal of Pharmaceutics and Biopharmaceutics
IS - 1
ER -